Taiwan says President Lai not blocked from US stopover
The remarks came after US President Donald Trump's administration reportedly denied permission for Lai to transit in New York as part of an official trip to Latin America next month.
Lai's office has never confirmed his travel plans, but Paraguay, Taiwan's only diplomatic ally in South America, said in mid-July that Lai would visit the country in 30 days.
Such a visit would likely mean Lai would need to fly through US territory.
"There has been no postponement, cancellation, nor any denial of permission for the transit by the US side," spokesman Hsiao Kuang-wei told reporters in Taipei.
"Given the ongoing post-disaster recovery efforts in southern Taiwan, the ongoing reciprocal tariff negotiations with the US, and the relevant international situation, the president has no plans for overseas visits in the near future."
The Financial Times, citing unnamed sources, reported on Tuesday that the Trump administration had denied permission for Lai to stopover in New York, after Beijing objected.
China claims Taiwan is part of its territory and opposes any international exchanges with the democratic island.
The Financial Times said Lai decided not to travel after he was told he could not enter New York.
Chinese and US officials are currently holding trade talks in Stockholm, in a bid to extend a fragile truce in the face of Trump's global tariff war.
While the United States does not recognise Taiwan as a country, Washington remains the island's most important partner and biggest arms supplier.
Commenting on the Financial Times article, the US former House speaker Nancy Pelosi said the decision "sends a dangerous signal".
"But once again, (Chinese) President Xi has achieved a victory over the values, security and economy of the United States in the Trump Administration blocking the democratically elected president of Taiwan from making a diplomatic trip through New York," Pelosi wrote on Facebook.
"Let us hope President Trump's denial of this stopover in New York is not indicative of a dangerous change in US policy on Taiwan."
A spokesperson for Washington's de facto embassy in Taiwan declined to comment on a "hypothetical" given Taipei had not announced Lai's travel plans.
But the American Institute in Taiwan spokesperson added: "Transits by high-level Taiwan officials, including presidents, are fully consistent with our longstanding policy and practice. That has not changed."
Lai had originally planned to stopover in New York and Dallas as part of the trip to Paraguay and Central American allies Guatemala and Belize next month, Bloomberg News previously reported.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
29 minutes ago
- Straits Times
Chinese soccer team train for inaugural World Humanoid Robot Games
Sign up now: Get ST's newsletters delivered to your inbox A T1 humanoid robot developed by Booster Robotics falls on a football pitch, during a practice in preparation for soccer competitions at the inaugural World Humanoid Robot Games, at the National Speed Skating Oval in Beijing, China August 1, 2025. REUTERS/Florence Lo BEIJING - On a soccer pitch in Beijing, "T1" is practising shots and taking up positions. T1 is no ordinary player, however, but a gold medal-winning humanoid robot training for the first World Humanoid Robot Games, taking place in Beijing from August 15. T1 is part of a race to take the lead in humanoid robotics, as China looks to become more self-sufficient in advanced technologies. The Games will bring together teams from more than 20 countries for events ranging from track and field to dance and martial arts, as well as practical applications such as industrial handling and medical services. T1 and its two teammates, fielded by Tsinghua University's Hephaestus team, made history for China last month by winning gold in the "Humanoid, adult size" category of the 28-year-old RoboCup Humanoid League in Brazil. "The Chinese government is actively promoting humanoid robot development," said Zhao Mingguo, Chief Scientist at Booster Robotics, maker of the T1. "To advance technology, the government is actively organising competitive events, and this sports games is one such experience." While some may dismiss such events as gimmicks, industry experts and participants see them as a decisive spur to advance humanoid robots toward practical real-world deployment. Although the Hephaestus team would hardly trouble even junior human opposition, Booster Robotics views soccer as a powerful test of perception, decision-making and control technologies that could later be applied in factories or homes. Top stories Swipe. Select. Stay informed. Tech Reporting suspected advanced cyber attacks will provide a defence framework: Shanmugam Business Singapore's US tariff rate stays at 10%, but the Republic is not out of the woods yet Asia Asia-Pacific economies welcome new US tariff rates, but concerns over extent of full impact remain Business ST explains: How Trump tariffs could affect Singapore SMEs, jobs and markets Asia Indonesia's Mount Lewotobi Laki-laki erupts Singapore Thundery showers expected on most days in first half of August Singapore Synapxe chief executive, MND deputy secretary to become new perm secs on Sept 1 Singapore 5 women face capital charges after they were allegedly found with nearly 27kg of cocaine in S'pore "Playing football is a testing and training ground for ... helping us refine our capabilities," Zhao said. And just as in real life, moving on from the training ground is often a challenge. Hephaestus is building on software developed for Brazil to improve the players' positioning skills. But the performance of humanoid robots still depends to a great extent on environmental variables such as the surface and hardness of the ground and the gradient of any slopes, according to Hephaestus's Chen Penghui. It wouldn't be the first time a soccer team had visited a new venue and bemoaned the state of the pitch. REUTERS
International Business Times
an hour ago
- International Business Times
Appeals Court Questions Trump's Use of Emergency Powers to Justify Tariffs
A US federal appeals court raised serious doubts about President Donald Trump's authority to impose broad tariffs under emergency powers. During a hearing in Washington, D.C., judges questioned whether the International Emergency Economic Powers Act (IEEPA) grants the president the legal right to impose tariffs on allied nations like Canada, China, and Mexico. Trump had used IEEPA to introduce what he called "reciprocal" tariffs in April and further increased them in February. The case now before the U.S. Court of Appeals for the Federal Circuit was brought by five small businesses and 12 Democratic-led states. They argue that Trump overstepped his powers and that only Congress has the constitutional right to set tariffs and taxes. Government lawyer Brett Shumate defended Trump's move, saying IEEPA gives the president broad authority in economic emergencies, including regulating imports. But Judge Jimmie Reyna responded, "IEEPA doesn't even mention tariffs." Several judges appeared skeptical throughout the 90-minute hearing, which concluded without a ruling date. The outcome of this case could have major implications. Trump, who made tariffs a key trade tool during his second term, claims they helped address unfair trade practices and boosted U.S. manufacturing. He cited the U.S. trade deficit and illegal fentanyl imports as justification. However, critics argue these reasons do not constitute an "extraordinary threat" under the law. Earlier this year, a lower court also ruled that IEEPA does not support tariffs based on long-term trade imbalances. The appeals court has allowed the tariffs to stay in place while legal challenges continue. With customs duties now generating over $100 billion in revenue this fiscal year, tariffs have become a significant funding source. Still, economists warn that they raise consumer prices and disrupt supply chains. The Trump administration argues that removing tariff power could harm trade negotiations, although recent deals with the EU, Japan, and others have moved forward. Trump has warned of further tariff hikes on countries not reaching new trade deals by August 1. The final decision in this case is likely to head to the U.S. Supreme Court if either side loses.
International Business Times
an hour ago
- International Business Times
Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary
US President Donald Trump has sent letters to 17 major pharmaceutical companies demanding they cut prescription drug prices in the United States. The letters, released Thursday by the White House, outline his plan to match U.S. prices with those in other developed countries. President Donald Trump addessses the nation after U.S. bombed Iran's nuclear facilities X Trump recently signed an executive order requiring drugmakers to offer "most-favored-nation" pricing. This means companies must sell medications to U.S. patients at the lowest price they offer elsewhere. If drug companies do not comply, Trump warned the government could import cheaper alternatives or take other steps. Companies that received the letters include Pfizer, Eli Lilly, Johnson & Johnson, Merck, Sanofi, and AstraZeneca. Trump had previously criticized earlier proposals from the industry, saying they prioritized profits over patient care. He also demanded that drugmakers return any excess profits made by raising prices overseas to compensate American taxpayers. Shares of major pharmaceutical firms fell after the announcement. Pfizer, Eli Lilly, and Gilead each dropped by around 2%, while a broader index of drug stocks declined 3%. Trump also suggested a system where companies can sell drugs directly to patients, bypassing middlemen, but only if they agree to international pricing rules. The president gave drugmakers a deadline of September 29 to respond with binding commitments. Health experts are skeptical that companies will meet Trump's demands. Some analysts believe the proposals are unlikely to result in immediate price changes, describing them as more political pressure than enforceable policy. Still, several companies, including Pfizer and Novartis, said they are open to working with the administration. Pfizer confirmed its ongoing talks with Trump officials to improve access and affordability for U.S. patients. U.S. drug prices remain among the highest in the world, with patients often paying nearly three times more than those in other developed countries. Drugmakers argue that sharp price cuts could harm innovation, but Trump insists bold action is needed to protect Americans from high costs.
